Biotech News
News | Bavarian Nordic
December 13, 2024 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
December 11, 2024 | Company Announcements
Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program
November 29, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
November 15, 2024 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
September 26, 2024 | Company Announcements
Bavarian Nordic Upgrades its Financial Guidance for 2024
September 26, 2024 | Company Announcements
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
September 24, 2024 | Company Announcements
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
September 18, 2024 | Company Announcements
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
September 13, 2024 | Company Announcements
Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine
September 05, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
August 22, 2024 | Company Announcements
Bavarian Nordic Announces First Half 2024 Results
August 21, 2024 | Company Announcements
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
August 13, 2024 | Company Announcements
Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa
August 13, 2024 | Company Announcements
Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its Chikungunya Vaccine
August 08, 2024 | Company Announcements
Bavarian Nordic Receives USD 156.8 Million from the U.S. Government for Additional Smallpox/Mpox Vaccine Production
July 18, 2024 | Company Announcements
Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
June 26, 2024 | Company Announcements
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
June 17, 2024 | Company Announcements
Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate
May 31, 2024 | Company Announcements
Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
May 22, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
May 21, 2024 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
May 21, 2024 | Company Announcements
EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
May 08, 2024 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
May 08, 2024 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
April 29, 2024 | Company Announcements
Bavarian Nordic Receives 65 mEUR Contract to Supply Smallpox Vaccines for EU Strategic Reserve